ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 2 filers reported holding ARRAY BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $264,000 | -48.9% | 5,700 | -73.1% | 0.02% | -50.0% |
| Q1 2019 | $517,000 | +28.6% | 21,200 | -24.8% | 0.03% | +18.5% |
| Q4 2018 | $402,000 | -6.3% | 28,200 | 0.0% | 0.03% | +8.0% |
| Q3 2018 | $429,000 | -9.3% | 28,200 | 0.0% | 0.02% | -10.7% |
| Q2 2018 | $473,000 | +2.8% | 28,200 | 0.0% | 0.03% | -3.4% |
| Q1 2018 | $460,000 | +27.4% | 28,200 | 0.0% | 0.03% | +26.1% |
| Q4 2017 | $361,000 | -64.8% | 28,200 | -87.5% | 0.02% | -85.6% |
| Q3 2015 | $1,026,000 | -36.7% | 225,000 | 0.0% | 0.16% | -36.3% |
| Q2 2015 | $1,622,000 | -2.2% | 225,000 | 0.0% | 0.25% | +9.1% |
| Q1 2015 | $1,658,000 | +233.6% | 225,000 | +114.3% | 0.23% | +228.6% |
| Q4 2014 | $497,000 | +32.5% | 105,000 | 0.0% | 0.07% | +20.7% |
| Q3 2014 | $375,000 | -21.7% | 105,000 | 0.0% | 0.06% | -21.6% |
| Q2 2014 | $479,000 | -3.0% | 105,000 | 0.0% | 0.07% | -5.1% |
| Q1 2014 | $494,000 | -6.1% | 105,000 | 0.0% | 0.08% | -8.2% |
| Q4 2013 | $526,000 | -62.4% | 105,000 | -53.3% | 0.08% | -68.0% |
| Q3 2013 | $1,400,000 | -5.1% | 225,000 | -30.8% | 0.27% | -1.1% |
| Q2 2013 | $1,476,000 | – | 325,000 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 9,719,589 | $60,456,000 | 10.40% |
| KOPP INVESTMENT ADVISORS LLC | 2,808,537 | $17,470,000 | 6.42% |
| Redmile Group, LLC | 3,669,593 | $22,825,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,585,406 | $65,841,000 | 3.06% |
| QVT Financial LP | 2,878,600 | $17,905,000 | 1.22% |
| APEX CAPITAL, LLC | 2,500,000 | $15,550,000 | 1.12% |
| FBR & Co. | 113,500 | $706,000 | 1.07% |
| Artal Group S.A. | 3,000,000 | $18,660,000 | 0.61% |
| Perimeter Capital Partners, LLC | 486,478 | $3,026,000 | 0.56% |
| Orbimed Advisors | 4,831,600 | $30,053,000 | 0.54% |